Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.

Summary, in English

Tasquinimod (a quinoline-3-carboxyamide) is a small molecule immunotherapy with demonstrated effects on the tumor microenvironment (TME) involving immunomodulation, anti-angiogenesis and inhibition of metastasis. A target molecule of tasquinimod is the inflammatory protein S100A9 which has been shown to affect the accumulation and function of suppressive myeloid cell subsets in tumors. Given the major impact of myeloid cells to the tumor microenvironment, manipulation of this cell compartment is a desirable goal in cancer therapeutics.

• Author: Anders Olsson; Jessica Nakhlé; Anette Sundstedt; Pascale Plas; Anne-Laure Bauchet; Valérie Pierron; Luce Bruetschy; Adnan Deronic; Marie Törngren; David Liberg; Fabien Schmidlin; Tomas Leanderson
• Department/s: Immunology; Stem Cell Center; BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
• Publishing year: 2015
• Language: English
• Publication/Series: Journal for ImmunoTherapy of Cancer
• Volume: 3
• Links: http://www.ncbi.nlm.nih.gov/pubmed/26673090?dopt=Abstract; http://dx.doi.org/10.1186/s40425-015-0098-5
• Document type: Journal article
• Publisher: BioMed Central (BMC)
• Topic: Cell and Molecular Biology
• Status: Published
• Research group: Immunology
• ISBN/ISSN/Other: ISSN: 2051-1426